The increased risk of genital tumors associated with psoralen plus ultraviolet A (PUVA) for the treatment of psoriasis appears to persist long after the treatment has been stopped or genital shielding has been employed, according to a report in the July issue of the Journal of the American Academy of Dermatology.
Previous reports have shown that treatment with PUVA can increase the risk of penile and scrotal squamous cell carcinomas, the authors note. To address this problem, most institutions implemented genital shielding protocols in the 1980s. Also, the use of PUVA has decreased in the last two decades.
However, the current report shows that despite the increased use of genital shielding and a decrease in PUVA use, men first treated with PUVA in the mid-1970s demonstrate a higher than expected rate of genital tumors more than 15 years later.
Dr. Robert S. Stern and colleagues, from Beth Israel Deaconess Medical Center in Boston, assessed the outcomes of 892 men who were first treated with PUVA for psoriasis between 1975 and 1976. The current study period ran from May 1989 to November 1998.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!